A strategic management initiative to expand and advance a multi-stage portfolio of novel development candidates through the discovery and in-licensing of antineoplastic drugs, cancer treatment adjuncts, and medical devices. Progress in the development of SP-05 is also positioned as part of this pipeline expansion.